Abstract
Efficient exogenous DNA integration can be mediated by Cas9 through the non-homology end-joining pathway. However, such integrations are often imprecise and contain a variety of mutations at the junctions between the external DNA and the genomic loci. Here we describe a microhomology-dependent targeted integration method, designated MITI, for precise site-specific gene insertions. We found that the MITI strategy yielded higher knock-in accuracy than Cas9 HITI for the insertion of external DNA and tagging endogenous genes. Furthermore, in combination with negative selection and four different CrRNAs targeting donor vectors and genome-targeted sites with a CrRNA array, MITI facilitated precise ligation at all junctions. Therefore, our Cas12a-based MITI method increases the repertoire of precision genome engineering approaches and provides a useful tool for various gene editing applications.
Electronic supplementary material
The online version of this article (10.1007/s00018-019-03396-8) contains supplementary material, which is available to authorized users.
Keywords: CRISPR, Genome editing, Homology-independent targeted integration, Negative selection, Sticky ends, Microhomology-dependent targeted integration
Introduction
Site-specific transgene integration is primarily implemented by homology-directed repair (HDR) and non-homology end joining (NHEJ) pathways [1]. The precise introduction of foreign DNA to endogenous target sites through the HDR pathway is time-consuming and cumbersome as it requires the cloning of the homology arms for every gene. Also, since this method can only exert its effect in the S/G2 cell phase, its efficiency is low, especially in non-dividing cells [2]. Accurate site-specific gene insertions could also be mediated via a method called Obligate Ligation-Gated Recombination (ObLiGaRe) through the efficient NHEJ pathway using zinc-finger nucleases (ZFNs) or Tale nucleases (TALENs) [3], but its wide application is limited by both high cost and complicated design. CRISPR/Cas9 also enables convenient and efficient knock-in of external DNA cassettes at target sites in zebrafish [4, 5], mammalian cells [6–8], and so on via NHEJ pathway; however, the junctions between the external DNA and the genome usually contain various mutations. Several efforts have aimed to optimize this system, such as controlling the expression of Cas9 protein via fusion of FKBP12-L106P destabilization domain to Cas9 [9] and cleaving both donor and target sites with the same sgRNA via homology-independent target integration (HITI) strategy [10].
Cas12a, as a newly identified RNA-guided nuclease of the Cas12 family, has several distinct advantages in comparison with Cas9, such as lower mismatch tolerance and greater specificity [11, 12]. Cas12a can process its CRISPR RNAs (CrRNAs) array into mature CrRNAs, and this facilitates concurrent targeting of multiple genes, which distinguishes it from Cas9 [13, 14]. Another difference between these two nucleases is that Cas9 and Cas12a generate blunt and sticky ends, respectively [15, 16]. Cas12a mainly cuts at the 18th base site of the non-complementary strand and the 23rd base site of the complementary strand downstream of the PAM sequence, generating a 5-nt overhang when the spacer length is 20 nt or longer. When the spacer length is shorter than 20 nt, Cas12a mainly cleaves after the 14 nt on the non-complementary strand and the 22 nt on the complementary strand. This feature makes Cas12a a useful tool similar to restriction enzymes for precise in vitro DNA assembly [17, 18]. The blunt-ended DSB generated by Cas9 is compatible with the Gibson assembly method, which relies on sequence homology for in vitro molecular cloning [19, 20]. Based on these in vitro comparison studies, we hypothesized that Cas12a may be used in mammalian cells for precise gene knock-in, with better accuracy than Cas9.
In this study, we devised a Cas12a-based method for precise gene integration. In this method, the recognition site is readily engineered into the donor vector by a simple PCR or T4 ligation. The orientation of Cas12a target sequences in the donor vector must be opposite to that of the genome target, but the 5 base pairs distal to the PAM are identical to the last 5 bp sequences of the genome target site, which enables the generation of seamless junctions between endogenous and exogenous DNA via complementary sticky sequences. Since our new method depends on the 5 bp microhomology, we denoted it as microhomology-dependent targeted integration (MITI). MITI could increase the accuracy of knock-in outcomes compared with the Cas9 HITI approach at several loci. Therefore, MITI is a useful tool for precise targeting.
Materials and methods
Plasmid cloning
The related primer sequences of plasmid and CrRNA constructions, knock-in detection, and T7E1 assays used in this study are noted in Supplementary Tables S1–S4. To generate the SA-IRES-GFP donor vector, the pZGs plasmid [21] was digested with NcoI, removing the LacZ-CAG promoter and allowing self re-ligation. The SV40-Puro fragment was PCR amplified and inserted into the AflII/BglII-digested pZGs backbone through Gibson assembly. The CrRNA or sgRNA target sequence of Cas12a or Cas9, respectively, was inserted into the XhoI/SpeI-digested donor backbone before the SA sequence to construct the single-cut donor vector, including D1, D2, and D3. To construct the D7 vector containing the HSV-TK negative selection gene, the linker carrying the other AAVS1 site CrRNA target sequence and the SalI enzyme cleavage site was inserted into the AscI/BglII-digested D2 backbone. A SalI/SpeI-digested TK1-Amp-ColE1 fragment from the pWS-TK7 plasmid was then ligated into the SalI/SpeI-digested vector backbone. Alternatively, donor vectors can be constructed by a simple PCR using the primers containing the target sequence to amplify the backbone fragment, followed by ligation with the reporter gene via Gibson assembly. The donor vector 3 × Flag-F2A-tdTomato-loxP-PGK-Puro-loxP was created through Gibson assembly, by combining the following five DNA fragments: (i) PCR-amplified 3 × Flag from pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene 42230), (ii) PCR-amplified F2A fragment from pMaster12 plasmid (Addgene 58527), (iii) PCR-amplified tdTomato fragment from pRSET-B tdTomato plasmid, (iv) the PCR-amplified loxP-PGK-Puro-loxP fragment, and (v) NdeI/AscI-digested pPB-hNRASG12V [22] piggyBac backbone. The corresponding CrRNA target sequence was inserted into the NdeI/FseI-digested 3 × Flag-F2A-tdTomato-loxP-PGK-Puro-loxP vector to obtain the D4, D5, and D6 donor vectors. To construct the D4.1 vector, the linker containing the CLTA Cas12a target sequence identical to the genome was ligated into the AscI/AflII-digested D4 vector. The vector for expressing the AsCas12a CrRNA was constructed via linking the direct repeat sequence of AsCas12a and the BbsI enzyme site sequence into the BbsI/BamHI digested pCRISPR-sg4 backbone [22]. To get the all-in-one vector co-expressing the hU6-CrRNA and AsCas12a, the hU6-CrRNA (BbsI) PCR fragment was ligated into the NruI digested pY010 plasmid (Addgene 69982) backbone through Gibson assembly. The CrRNA array was constructed as previously described [14].
Cell culture and transfection
HEK293T cells, HeLa cells, HepG2 cells and the primary pig fetal fibroblasts (PFFs) cells were all grown at 37 °C, in 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) containing l-glutamine and pyridoxine hydrochloride supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1 mM sodium pyruvate, 1 × NEAA and 1% penicillin and streptomycin. Cells were dissociated using 0.05% trypsin into single cells after washing in phosphate buffer saline and transfected using 4D-Nucleofector. For each transfection, 106 cells were mixed with 100 μL pre-warmed nucleofection reagents. The cell suspensions were then mixed with plasmids and electroporated with a 4D-Nucleofector Device (Lonza). Transfected cells underwent puromycin selection for 5 days to ensure successful transfection and were then analyzed by flow cytometry (BD FACS Calibur).
T7E1 assay
To prepare the genomic DNA from the cells for the T7E1 assay, cells were treated with 500 μL ES cells lysis buffer (100 mM NaCl; 20 mM Tris, pH 7.6; 10 mM EDTA; 0.5% SDS) and 15 μL of proteinase K (from 10 mg/mL stock) at 37 °C for 2–4 h without shaking. The genomic DNA was extracted as previously described [23]. Prior to PCR, 5 μL of genomic DNA was diluted in 15 μL HotShot lysis solution (25 mM NaOH, 0.2 mM EDTA), boiled for 15 min, and then neutralized with 15 μL of 40 mM Tris–Cl. The genomic region flanking the target site for each gene was PCR amplified using Q5 High-Fidelity DNA Polymerase (New England Biolabs, M0491S) following the manufacturer’s instructions. The 200–500 ng purified PCR fragments were mixed with 1 μL 10 × PfuUltra II Reaction Buffer (Agilent) and sterile ultra-pure water to a final volume of 10 μL and were subjected to a re-annealing process to enable heteroduplex formation: 95 °C for 10 min, 95 °C to 85 °C ramping at 2 °C/s, 85 °C to 25 °C at 0.25 °C/s, and 25 °C hold for 1 min. After re-annealing, the products were treated with 10 U of T7E1 enzyme (New England Biolabs) in 15 μL of the reaction mixture at 37 °C for 1 h, and the digested fragments were directly resolved on polyacrylamide gels. The Indel percentage was calculated with the following formula: 100 × (1 − sqrt (1 − (b + c)/(a + b + c))), where “a” represents the gray value of the intact band, and “b” and “c” are the gray values of each cleavage band. The gray values were determined using Image J software.
Junction DNA sequencing by TA cloning
For junction sequence analysis after targeted knock-in, the genomic DNA of pooled cells or picked clones was extracted as described above. The target sites were PCR amplified using the Herculase II Fusion Enzyme (Agilent Technologies, Catalog #600677). For sequence analysis of the PCR product from pooled cells, GoTag polymerase (Agilent Technologies) was used to tail the PCR products, which were then cloned into the pMD19-T vector backbone (TakaRa, Catalog #6013) and sent for sequencing. For direct sequence analysis of the 5′ and 3′ junctions of picked clones, the PCR products were directly purified and sent for sequencing.
Immunofluorescence staining
The HepG2 cells with stably integrated 3 × FLAG-2A-tdTomato reporter were washed with PBS and fixed in 4% paraformaldehyde for 30 min at room temperature. After washing three times in PBS every 5 min, the cells were blocked with blocking buffer (Beyotime Biotechnology, P0102) for 1 h at room temperature. The cells were then incubated overnight at 4 °C with the anti-FLAG-tag primary antibody (Beyotime Biotechnology, AF0036, 1:100). Next, the cells were incubated with the goat anti-rabbit IgG secondary antibody (Invitrogen, 1:1000) for 30 min in the dark after removing the primary antibody. Finally, DAPI (1:10,000) in PBS was added into the cells for 1 min. The immunostained cells were examined by fluorescence microscopy.
Results
Cas12a MITI strategy could facilitate more precise targeted integration
To test the effect of Cas12a sticky overhangs on the outcomes of targeted integrations, we designed two simple strategies: Cas12a HITI and Cas12a MITI, which are different in that the 5 bp PAM-distal sequences are oriented in opposite directions (Fig. 1a, b). The sticky end generated by Cas12a on the donor plasmid in MITI is complementary with that of the endogenous target site. For comparison, the accuracy of the Cas9 HITI strategy was also examined (Fig. 1c). We next tested these strategies for targeting the reporter gene cassette—SA-IRES-GFP-SV40-Puro—into an editable AAVS1 locus (Figs. 2a, S1). We first selected an overlapping target site at the AAVS1 locus that can be cleaved simultaneously by Cas9 and Cas12a. We transfected HeLa cells with the corresponding Cas12a or Cas9 targeting vectors and donor plasmids and performed flow cytometry analysis for GFP-positive cells after 5 days of puromycin selection. After Sanger sequencing the TA-cloned 5′- and 3′-junction PCR products of the Cas12a HITI, Cas12a MITI, and Cas9 HITI HeLa cells, we found that 70% of Cas12a MITI-mediated integrations were accurate at the 5′ junctions, whereas precision of Cas9 HITI integrations was only 16.67%, and Cas12a HITI had no precise integrations (Figs. 2b, S2A-D). At the 3′ junction, precision of Cas12a MITI-mediated integrations was less accurate (Fig. S2E), possibly due to re-digestion by Cas12a after integration. In brief, these results suggested Cas12a MITI facilitates efficient precise targeted integration. It should be noted that potential large deletions of GFP were not considered when analyzing the above results. However, this should not bias our conclusions since all three methods were analyzed the same way.
MITI allows for more efficient seamless reporter gene tagging
To compare the accuracy of Cas12a MITI and Cas9 HITI, we next used a 2A-tdTomato reporter system to tag a constitutively expressed gene CLTA in 293T cells (Fig. 3a). By flow cytometry analysis, we found that Cas12a MITI had a significantly higher percentage of tdTomato positive cells (14.40 ± 2.40%) than Cas9 HITI (5.30 ± 1.10%) (P = 0.026, Fig. 3b) after 5 days of puromycin selection. This low frequency of precise integration may be due to the existence of an identical target sequence for both Cas12a and Cas9 in the CLTA pseudogene on chromosome 12. The 5′-end integration junction of unsorted cells was amplified for sequence analysis, which showed that Cas12a MITI had a higher in-frame and precise integration rate than Cas9 HITI (Figs. 3c, S3). We further tested Cas12a MITI for targeting the silenced gene GREB1L with 2A-tdTomato in porcine fibroblasts (Fig. S4A). After transfection and puromycin selection, we picked 24 cell clones for PCR and sequencing analysis (Fig. S4B). We found that 91.67% of clones had the targeted integration at the 5′ junction and 81.82% of the integrations had the expected junction sequence (Fig. S4C). The above results further demonstrated that Cas12a MITI can be strategically used for more precise reporter gene targeting.
Two cleavages in the donor help exclude unintended integration of the plasmid backbone
To avoid integration of unwanted donor plasmid backbone, which may result in pronounced transgene silencing [10], a second Cas12a recognition sequence with perfect homology to the genome target sequence was added to the CLTA donor plasmid behind the puromycin gene (Fig. 4a). After transfection into HepG2 cells and 5 days of puromycin selection, we picked 16 tdTomato-positive clones. PCR and sequencing results showed 10 out of 16 tdTomato-positive cells had the predicted 5′ junction sequence (Fig. 4b, c), and 8 out of 16 clones were successfully targeted without the integration of the plasmid backbone (Fig. 4b, d). Further verification of these successful tagging events was confirmed with immunostaining (Fig. S5). These results indicate that Cas12a MITI can readily avoid plasmid backbone integration.
Improved accuracy of both junctions with two cleavage sites on MITI donors
To improve the sequence fidelity of both junctions between endogenous DNA and the exogenous gene, we selected two different neighboring genomic sites to target, and placed the corresponding MITI recognition sites around the foreign reporter gene in the donor vector. Meanwhile, we also introduced a herpes simplex virus thymidine kinase (HSV-tk) suicide cassette—a negative selection marker for avoiding random integration of the targeting vector [24, 25]—positioned outside of the reporter gene to exclude unintended genomic integration of donor plasmid (Fig. 5a). Two MITI cleavages on the donor plasmid eliminate the HSV-tk suicide gene along with cell sensitivity to Fialuridine (FIAU). After transfection and drug selection, we picked puromycin and FIAU dual resistant clones and analyzed both 5′ and 3′-end junction sequences by PCR sequencing. We found that in the puromycin and FIAU dual resistant clones, precise 3′ junction integration efficiency was improved (Fig. 5b, c). Our results suggest that two cleavage sites in combination with negative selection facilitate precise targeted integration of exogenous genes at both junctions. However, when using pairs of CrRNAs, complicated repair events may occur [26], and should be further examined in the future.
Discussion
In this study, we demonstrated that sticky ends generated by Cas12a could facilitate the precise integration of foreign DNA fragments into the target genomic locus. The MITI method relies on Cas12a-induced stable complementary sticky overhangs which can enhance the efficiency and precision of in situ reporter gene targeting, and consequently greater fidelity of targeted gene expression. Our side-by-side comparison experiment revealed that the accuracy of end joining with MITI tends to be higher than the Cas9 HITI strategy at the different loci tested. MITI could be an alternative tool for future gene therapy applications. However, it should be noted that the method we used has some limitations. The number of colonies analyzed in the current study is still small. The results could be further strengthened using NGS.
Using a dual MITI strategy, we demonstrated the feasibility of precisely replacing a segment of DNA with the desired external DNA sequence via simultaneous cleavage of two neighboring sites in the genome and two corresponding target sites in the donor vector flanked by a negative selection cassette. In contrast, the Cas9 HITI strategy is currently capable of inserting foreign DNA into only a single genomic locus. This dual MITI strategy may be useful in certain situations, such as adding the loxP sequences to both sides of the exon for constructing conditional knockout animals or substituting the whole target gene with the desired coding sequences.
When tagging endogenous genes with a reporter, Cas9-mediated homology-independent knock-in via HITI always deletes the last few codons of the gene, destroying its integrity, which might have an impact on the function of the gene. For example, in our study, when the reporter cassette was used to tag the human CLTA gene using a Cas9 HITI approach, six base pairs were inevitably deleted (Fig. S3). Our MITI approach avoided such genetic deletion by adding essential base pairs after the cleavage site in the donor making it more flexible than the Cas9 HITI method.
Nonetheless, further examination of potential limitations and optimization of the MITI method is required. For example, widespread nickase activity of Cas12a [27–29] has been reported and may cause random insertion of foreign genes. However, since the fidelity of Cas12a is higher than Cas9 nuclease [11, 12], MITI is likely to have fewer off-target integrations than Cas9 HITI. Furthermore, when using pairs of CrRNAs for dual Cas12a targeting at two different loci, complicated repair events may occur, similar to that seen for CRISPR/Cas9, including the formation of extrachromosomal circular DNA, DNA inversion, and translocation [26]. This should be further tested and verified in the future. Considering there are many kinds of Cas12 with different specificities, potencies and PAM dependence [17, 30–33], it is possible to extend editable sequence space and enable further optimization of our MITI method.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgements
We are grateful for continuous support from the Wu lab members. This work was supported by the Transgenic Research Grant 2016ZX08010001, the Transgenic Research Grant 2016ZX08009003, and Project for Extramural Scientists of State Key Laboratory of Agrobiotechnology (Grant no. 2016SKLAB1-8).
Abbreviations
- MITI
Microhomology-dependent targeted integration
- HITI
Homology-independent targeted integration
- CRISPR
Clustered regularly interspaced short palindromic repeats
- CrRNAs
CRISPR RNAs
- DSB
Double-strand break
- NHEJ
Non-homology end joining
- HDR
Homology-directed repair
- GOI
Gene-of-interest
- ZFNs
Zinc finger nucleases
- ObLiGaRe
Obligate ligation-gated recombination
- TALENs
Tale nucleases
- PFFs
Pig fetal fibroblasts
- HSV-tk
Herpes simplex virus thymidine kinase
Author contributions
SW, XD, PL, and CX conceived and designed the experiments. PL, LZ, and ZL performed the experiments. SW, XD, PL, and CX wrote and edited the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Pan Li and Lijun Zhang contributed equally to this work.
Contributor Information
Xuguang Du, Email: xuguangdu@cau.edu.cn.
Sen Wu, Email: swu@cau.edu.cn.
References
- 1.Yamamoto Y, Gerbi SA. Making ends meet: targeted integration of DNA fragments by genome editing. Chromosoma. 2018;127:405–420. doi: 10.1007/s00412-018-0677-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Annu Rev Genet. 2010;44:113–139. doi: 10.1146/annurev-genet-051710-150955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Maresca M, Lin VG, Guo N, Yang Y. Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res. 2013;23:539–546. doi: 10.1101/gr.145441.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Auer TO, Duroure K, De Cian A, et al. Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res. 2014;24:142–153. doi: 10.1101/gr.161638.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kimura Y, Hisano Y, Kawahara A, Higashijima SI. Efficient generation of knock-in transgenic zebrafish carrying reporter/driver genes by CRISPR/Cas9-mediated genome engineering. Sci Rep. 2014;4:6545. doi: 10.1038/srep06545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bachu R, Bergareche I, Chasin LA. CRISPR-Cas targeted plasmid integration into mammalian cells via non-homologous end joining. Biotechnol Bioeng. 2015;112:2154–2162. doi: 10.1002/bit.25629. [DOI] [PubMed] [Google Scholar]
- 7.He X, Tan C, Wang F, et al. Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 2016;44:e85. doi: 10.1093/nar/gkw064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Lackner DH, Carré A, Guzzardo PM, et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat Commun. 2015;6:10237. doi: 10.1038/ncomms10237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Geisinger JM, Turan S, Hernandez S, et al. In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucleic Acids Res. 2016;44:e76. doi: 10.1093/nar/gkv1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature. 2016;540:144–149. doi: 10.1038/nature20565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kim D, Kim J, Hur JK, et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol. 2016;34:863–868. doi: 10.1038/nbt.3609. [DOI] [PubMed] [Google Scholar]
- 12.Kleinstiver BP, Tsai SQ, Prew MS, et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol. 2016;34:869–874. doi: 10.1038/nbt.3620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Fonfara I, Richter H, BratoviÄ M, et al. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature. 2016;532:517–521. doi: 10.1038/nature17945. [DOI] [PubMed] [Google Scholar]
- 14.Zetsche B, Heidenreich M, Mohanraju P, et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat Biotechnol. 2017;35:31–34. doi: 10.1038/nbt.3737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821. doi: 10.1126/science.1225829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759–771. doi: 10.1016/j.cell.2015.09.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Li SY, Zhao GP, Wang J. C-Brick: a new standard for assembly of biological parts using Cpf1. ACS Synth Biol. 2016;5:1383–1388. doi: 10.1021/acssynbio.6b00114. [DOI] [PubMed] [Google Scholar]
- 18.Lei C, Li SY, Liu JK, et al. The CCTL (Cpf1-assisted Cutting and Taq DNA ligase-assisted Ligation) method for efficient editing of large DNA constructs in vitro. Nucleic Acids Res. 2017;45:e74. doi: 10.1093/nar/gkx018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jiang W, Zhao X, Gabrieli T, et al. Cas9-Assisted Targeting of CHromosome segments CATCH enables one-step targeted cloning of large gene clusters. Nat Commun. 2015;6:8101. doi: 10.1038/ncomms9101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wang JW, Wang A, Li K, et al. CRISPR/Cas9 nuclease cleavage combined with Gibson assembly for seamless cloning. Biotechniques. 2015;58:161–170. doi: 10.2144/000114261. [DOI] [PubMed] [Google Scholar]
- 21.Wu S, Ying G, Wu Q, Capecchi MR. Toward simpler and faster genome-wide mutagenesis in mice. Nat Genet. 2007;39:922–930. doi: 10.1038/ng2060. [DOI] [PubMed] [Google Scholar]
- 22.Xu C, Qi X, Du X, et al. piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice. Proc Natl Acad Sci USA. 2017;114:722–727. doi: 10.1073/pnas.1615735114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wu S, Ying G, Wu Q, Capecchi MR. A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond. Nat Protoc. 2008;3:1056–1076. doi: 10.1038/nprot.2008.70. [DOI] [PubMed] [Google Scholar]
- 24.Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988;336:348–352. doi: 10.1038/336348a0. [DOI] [PubMed] [Google Scholar]
- 25.Wu S, Wu Y, Zhang X, Capecchi MR. Efficient germ-line transmission obtained with transgene-free induced pluripotent stem cells. Proc Natl Acad Sci USA. 2014;111:10678–10683. doi: 10.1073/pnas.1409933111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Møller HD, Lin L, Xiang X, et al. CRISPR-C: circularization of genes and chromosome by CRISPR in human cells. Nucleic Acids Res. 2018;46:e131. doi: 10.1093/nar/gky767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Fuchs RT, Curcuru J, Mabuchi M, et al. Cas12a trans-cleavage can be modulated in vitro and is active on ssDNA, dsDNA, and RNA. bioRxiv. 2019 doi: 10.1101/600890. [DOI] [Google Scholar]
- 28.Murugan K, Seetharam AS, Severin AJ, Sashital DG. Pervasive off-target and double-stranded DNA nicking by CRISPR-Cas12a. bioRxiv. 2019 doi: 10.1101/657791. [DOI] [Google Scholar]
- 29.Fu BXH, Smith JD, Fuchs RT, et al. Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9. Nat Microbiol. 2019;4:888–897. doi: 10.1038/s41564-019-0382-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Sun H, Li F, Liu J, et al. A single multiplex crRNA array for FnCpf1-mediated human genome editing. Mol Ther. 2018;26:2070–2076. doi: 10.1016/j.ymthe.2018.05.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Tu M, Lin L, Cheng Y, et al. A ‘new lease of life’: FnCpf1 possesses DNA cleavage activity for genome editing in human cells. Nucleic Acids Res. 2017;45:11295–11304. doi: 10.1093/nar/gkx783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Teng F, Cui T, Feng G, et al. Repurposing CRISPR-Cas12b for mammalian genome engineering. Cell Discov. 2018;4:63. doi: 10.1038/s41421-018-0069-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Strecker J, Jones S, Koopal B, et al. Engineering of CRISPR-Cas12b for human genome editing. Nat Commun. 2019;10:212. doi: 10.1038/s41467-018-08224-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.